TransGenic Inc - Company Profile
Powered by 
All the data and insights you need on TransGenic Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date TransGenic Inc Strategy Report
- Understand TransGenic Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
TransGenic Inc (TransGenic) is a biotechnology company that develops and distributes genetically engineered animals and antibodies and licensing of these activities. The company’s product portfolio and services include knockout mouse and phenotype database, custom production of antibodies and proteins, genetically engineered mice, custom production of knock out mouse, drug discovery and contract services for non-clinical study, support services, mouse related products, and antibody related products. TransGenic provides gene analysis and nonclinical study using disease-animal model. The company’s technologies include genetically engineered mouse knock in mouse and knockout mouse; genome editing technology; exchangeable Gene-trap method, among others. It has Kobe research center located in Japan. TransGenic is headquartered in Fukuoka City, Japan.
Headquarters
Japan
Address
Ibbfukuoka Bldg., 2-3-36, Tenjin, Chuo-Ku, Fukuoka-Shi, 810-0001
Website
www.transgenic.co.jp
Telephone
81 92 2888470
No of Employees
236
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
2342 (TYO)
Revenue (2023)
$84.4M
13.9%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
243.5%
(2023 vs 2022)
Market Cap*
$28.8M
Net Profit Margin (2023)
XYZ
-124.0%
(2023 vs 2022)
* As of and is in US$
TransGenic Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| - | - |
| Knockout Mouse | Preclinical Research Services |
| Phenotype Database | Contract Services for Non- clinical study |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In March, the company entered into a partnership agreement with Kurume Research Park to establish consolidated biopharmaceutical development network. |
| 2023 | Acquisitions/Mergers/Takeovers | In March, the company acquired MASC. |
| 2021 | Contracts/Agreements | In September, the company entered into an agreement to acquire Lunapas LLC. |
Competitor Comparison
| Key Parameters | TransGenic Inc | Anhui Anke Biotechnology (Group) Co Ltd | ABIONYX Pharma SA | Central Institute for Experimental Animals | Daiichi Sankyo Taiwan Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | China | France | Japan | Taiwan |
| City | Fukuoka-Shi | Hefei | Balma | Kawasaki | Taipei |
| State/Province | Fukuoka | Anhui | Haute Normandie | Kanagawa | Taipei |
| No. of Employees | 236 | 3,003 | 63 | - | - |
| Entity Type | Public | Public | Public | Institution | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kenji Fukunaga | Director; Chief Executive Officer; President | Executive Board | 2013 | 54 |
| Tsutomu Seito | Director | Executive Board | - | - |
| Shunichi Kitajima | Director | Executive Board | - | 63 |
| Kazuo Watanabe | Director | Executive Board | - | 56 |
| Hotaka Saito | Director | Executive Board | - | 65 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer